GSK Arexvy Protects From RSV Over Three Full Seasons
glaxosmithkline (GSK.US) claimed that the protection of the RSV vaccine can last for three quarters.
glaxosmithkline (GSK.US) stated on Tuesday that its respiratory syncytial virus (RSV) vaccine has protective effects in the three quarters after vaccination.
UK Court Sides With Pfizer, BioNTech in MRNA Patent Case Against CureVac
Guggenheim Adjusts Pfizer Price Target to $36 From $35, Maintains Buy Rating
Watch These Pfizer Price Levels as Stock Gains After Report of Starboard Taking Stake
2 Covered Call Ideas on Pfizer Stock
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
A rising market must decline.
